MaiKang Digital received several million dollars in seed funding
Miankang Digital Intelligence and Nunchux AI completed a seed financing in September 2026. The funds were allocated to the development of GLP-1 digital therapies and multi-mode…
In September 2026, two AI companies announced the completion of their seed round of financing. Meddcom AI was led by the incubation platform of YZi Labs under Zhao Changpeng, with additional funding from Gaozhang Capital, Ricture’s founder, and Oak Grove Ventures. The funds will be used for the research and development, clinical testing, and market expansion of its GLP-1 weight loss and diabetes management digital therapy products. Nunchux AI received funding from Emergence Capital and the E14 Fund of MIT Media Lab, with the funds intended for the development of a multimodal reasoning acceleration engine, team expansion, and initial client engagements.
E14Emergence CapitalGaozang CapitalLilyShuoMITMaiKang Digital IntelligenceNunchux AIOak Grove VenturesYZi Labs
Event frameEVENT FRAME
Funding / M&A数百万美元
迈康数智获赵长鹏旗下YZi Labs领投
Status
Miankang Digital Intelligence and Nunchux AI completed a seed financing in September 2026. The funds were allocated to the development of GLP-1 digital therapies and multi-mode…
Coverage · reports per dayLANGUAGE SPLIT
Entity relations
Integrated timelineUNIFIED TIMELINE
2026-09-07
Miankang Digital Intelligence and Nunchux AI received millions of dollars in seed financing.
Miankang Digital Intelligence was led by YZi Labs, with participation from Gaozang Capital, Risyue’s founder, and Oak Grove Ventures; Nunchux AI was led by Emergence Capital and MIT Media Lab’s E14 Fund.
In September 2026, AI medical technology company Meddcom AI announced the completion of a seed financing round worth several million dollars. This round was led by YZi Labs, a platform under Zhao Changpeng, with participation from Gaozhang Capital, Rictis’ founder, and Oak Grove Ventures. The company focuses on the consumer healthcare sector, specializing in medical-grade digital therapy products for GLP-1 weight loss and blood sugar control. By integrating artificial intelligence, it offers an integrated solution of “medication + digital support” aimed at creating a personalized “health profile” for users. The funds will be used for product research and development, clinical validation, and market expansion.
In September 2026, Nunchux AI, a developer of multimodal inference acceleration engines, announced the completion of a seed round financing of several million dollars, led by Emergence Capital and E14 Fund under MIT Media Lab. The company is based in the United States and focuses on improving the efficiency of large-scale AI model inference to achieve faster and lower-cost deployment. This funding will be used to accelerate the development of core engines, expand the team, and onboard early customers. This move indicates that the emerging AI infrastructure sector has once again received attention from investors.